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VIEWPOINT

Continuing Medical Education and Pharmaceutical Industry
Farhan Saeed Vakani1, Wasim Jafri1, Almas Amin2 and Mughis Sheerani3

ABSTRACT
Continuing medical education providers' (academia) and industrial relationship is drawing attention all over the world. To
date, there are no national commercial support guidelines available in Pakistan to properly regulate cooperation between
the two distinct entities. However, the fact is that the future of all continuing medical education depends on pharmaceutical
support and the providers are heavily dependent on the pharmaceutical industry to remain in action. It should always be
remembered that medical education and profession is regarded as a moral of enterprise based on a blind faith between
the physician and the patient. The funding support by the industry should not bind or influence physician's prescription for
any reason. To be trusted, medicine must be free of all such dependency; it should be accountable only to the society it
serves and to its own professional standards.
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Continuing Medical Education and Industrial support:
This is a fact that all CME (Continuing Medical
Education) providers i.e. academia, rely heavily on
financial support from pharmaceutical industry to remain
in business. “For smooth translation of the continuing
education and to persist, commercial funding must
remain healthy. The future of CME depends on pharmaceutical support”.1
The study by Smith et al.2 provided the evidence that
commercial support of individual CME programs was
prevalent among all types of provider organizations.2 In
the author's recent research (unpublished work) on
exploring the learning needs of the physicians, (80%) of
the physicians rated local CME activities excellent when
organized in collaboration with the academic institutions
and pharmaceutical industry.

Alternatives: The CME providers without this infusion of
funding from the pharmaceutical industry would be
remote and would have to find other resources to meet
the actual cost of the programming. The CME providers
in the academic community would be hard pressed to
receive financial support from institutions. Often, the
only funding available is earmarked for administrative
support. Perhaps, there may be organizations that
contribute some seed funding for pilot activities of the
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The very next possibility for the providers when not
entertaining funds from the industry is to charge higher
registration fees from the participatory physicians to
meet the actual cost of the program. Again this is not a
realistic approach. It really opposes the existing culture
in which the physicians expect to obtain continuing
education at minimal or no financial cost.3
Considerations: The importance and provision of the
funds from the pharmaceutical industry for CME
promotion in this part of the world is not to be neglected.
Research indicates that industry funding can skew CME
activities in various ways to match the goals of industry.4
Given that, the ethical aspect which triggers the CME
providers need to define and determine the appropriate
boundaries between them and the pharmaceutical
industry. It must not be forgotten what CME is all about?
physician-learners and their patients. In that vein,
following steps may be adopted:
Efforts should be taken by the academia and the
industry to organize, dialogue and develop national
commercial support guidelines for Pakistan.4
The CME providers (academia) should be vigilant to
control the commercial supporters influence on the
continuing educational activity.
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CME office. On the contrary, the CME office is often
viewed as one that should be a source of profit for the
academic institution, the department, or, at the very
least, the program director of the activity.3

The curriculum for continuing medical education should
be entirely in the hands of the academia and funding
should not compromise, or even call into question, the
integrity and independence of what is taught.
Full-time faculty at medical schools and teaching
hospitals should be expected to teach in the CME
programs of their institutions. This would reduce costs
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and form independence of the academic settings and
probably improve the quality of the CME activities.5

honest relationships. It is time for the leadership of the
medical profession and the CME providers to make it
clear to an increasingly skeptical public that academicians, and not the pharmaceutical industry, are in
charge of the continuing education of physicians.
Industry and the medical teaching institutions should
each recognize their separate and distinct responsibilities, and should not encroach on the other's
sphere.

To maintain transparency, financial contributions by the
industry should be deposited to a central repository of
funds, which, in turn, would disburse funds to that
continuing medical education activity.1
Academia should clearly spell the contribution of the
commercial industry, so that physician-learners can
recognize the degree of support.
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